U.S. Pharmaceuticals & Biotech Most Popular Stocks

Avenir Wellness Solutions

Market Cap: US$9.0k

Together with its subsidiary, The Sera Labs, Inc., engages in the development of nutraceutical formulation and delivery technologies in dosage forms for wellness.

MJardin Group

Market Cap: US$9.0k

Through its subsidiaries, cultivates, harvests, processes, and sells cannabis products in Canada and the United States.

Biostax

Market Cap: US$8.6k

Operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products.

Chalice Brands

Market Cap: US$8.4k

Engages in the retail, production, processing, wholesale, and distribution of cannabis products.

Anbc

Market Cap: US$8.0k

Shanghai Yutong Pharma, Inc. engages in the development, manufacturing, and commercialization of traditional Chinese herbal medicines and biological pharmaceuticals in the People’s Republic of China.

Avivagen

Market Cap: US$7.8k

Focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity.

Winston Pharmaceuticals

Market Cap: US$7.7k

A pharmaceutical company, discovers, develops, and commercializes therapeutics for pain management.

0913693 B.C

Market Cap: US$7.4k

A regenerative medicine company, develops autologous cell therapies for the treatment of functional cellular deficits.

Statera Biopharma

Market Cap: US$7.3k

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis.

Therapeutic Solutions International

Market Cap: US$7.0k

Therapeutic Solutions International, Inc.

Myrexis

Market Cap: US$6.9k

Focuses on identifying, evaluating, and making financial investments in life sciences assets.

AVAX Technologies

Market Cap: US$6.9k

A development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer.

Bloomios

Market Cap: US$6.8k

Manufactures, markets, and distributes cannabidiol products.

WOWI

Market Cap: US$6.6k

An early-stage company, engages in the business of licensing technology and intellectual property to operators and businesses in the legal cannabis industry in the United States.

CEN Biotech

Market Cap: US$6.5k

Focuses on the manufacture, production, and development of light emitting diode lighting technology and hemp-based products.

White Label Liquid

Market Cap: US$6.4k

Provides manufacturing service for custom-blended products containing hemp-derived CBD oil.

Theralink Technologies

Market Cap: US$6.2k

A commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of oncology products in the United States.

Wuhan General Group (China)

Market Cap: US$5.5k

Through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr.

Aida Pharmaceuticals

Market Cap: US$5.4k

Engages in the formulation, clinical testing, registration, manufacture, sales, and marketing of pharmaceutical and genetic products in mainland China.

MultiCell Technologies

Market Cap: US$5.0k

A biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications.

TetraLogic Pharmaceuticals

Market Cap: US$4.9k

A clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases.

Canopus BioPharma

Market Cap: US$4.6k

A pharmaceutical research company, provides pharmaceutical products and assay methods to patients suffering from infectious, cancer, and addiction diseases.

Innovation1 Biotech

Market Cap: US$4.5k

Researches, develops, produces, and sells pharmaceutical products in the United States.

Dakshidin Corporation

Market Cap: US$4.4k

Through its subsidiaries, operates as a CBD/cannabis-based medical product company.

Baseline Productions

Market Cap: US$4.1k

Does not have significant operations.

Xeno Transplants

Market Cap: US$4.0k

Operates as a bio-technology research and development company.

Quick-Med Technologies

Market Cap: US$3.7k

A life sciences company, focuses on developing and commercializing proprietary broad-based technologies in medical and consumer healthcare markets.

Black Bird Biotech

Market Cap: US$3.7k

Black Bird Biotech Inc. provides various biotech products.

Synovics Pharmaceuticals

Market Cap: US$3.6k

Through its subsidiaries, engages in the development, manufacture, and commercialization of generic over-the-counter (OTC) pharmaceutical products and generic prescription drug products primarily in the United States.

Korver

Market Cap: US$3.6k

Engages in the design and manufacture of integrated machine controls that are sold to manufacturers of plastic parts for the automotive, household products, and electronics industries worldwide.

Golden Age Resources

Market Cap: US$3.4k

Golden Age Resources Inc., an acquisition and development company, focus on the development of prescription and over the counter medicines in the United States.

Todos Medical

Market Cap: US$3.3k

A vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States.

Rebus Holdings

Market Cap: US$3.2k

Focuses on the research and development of precision therapeutics for the treatment of cancer.

Comera Life Sciences Holdings

Market Cap: US$3.1k

A preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform.

BZAM

Market Cap: US$2.7k

Operates as a cannabis producer with a focus on branded consumer goods.

Neurobiological Technologies

Market Cap: US$2.7k

Operates under a plan of liquidation and dissolution approved by stockholders in October 2009.